Scientific Publications

Legend Biotech sponsors research with academic institutions to evaluate our agents. The manuscripts from this research are presented below.

Year :

The Patient Experience of Relapsed Refractory Multiple Myeloma and Perspectives on Emerging Therapies

R Crawford, KS Gries, S Valluri, J Fastenau, R Morrison, T-M Yeh, Y Olyslager, JD Goldberg, JM Schecter, CJ Jackson, W Deraedt, L Doward

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry

M Merz, H Goldschmidt, P Hari, M Agha, J Diels, F Ghilotti, NJ Perualila, J Cabrieto, B Haefliger, H Sliwka, JM Schecter, CC Jackson, Y Olyslager, M Akram, T Nesheiwat, L Kellermann, S Jagannath

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE‑1 vs Physician’s Choice of Therapy in the Long‑Term Follow‑Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

K Weisel, T Martin, A Krishnan, S Jagannath, A Londhe, S Nair, J Diels, M Vogel, JM Schecter, A Banerjee, JG Berdeja, T Nesheiwat, A Garrett, K Qi, S Valluri, SZ Usmani, K Yong

Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US

S Jagannath, N Joseph, J He, C Crivera, AZ Fu, A Garrett, N Shah

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

T Martin, SZ Usmani, JM Schecter, M Vogel, CC Jackson, W Deraedt, H Tian, T Yeh, A Banerjee, L Pacaud, A Garrett, A Haltner, C Cameron, S Van Sanden, J Diels, S Valluri, IA Samjoo